--- title: "Pre-market hot trades in US stocks: XCF Global up 14.94% in pre-market; INVO Fertility down 12.23% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/291115098.md" description: "XCF Global pre-market up 14.94%; INVO Fertility pre-market down 12.23%; Nature's Way pre-market up 222.30%; Decoy Therapeutics pre-market up 207.90%; Inlif pre-market up 58.89%" datetime: "2026-06-29T08:42:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291115098.md) - [en](https://longbridge.com/en/news/291115098.md) - [zh-HK](https://longbridge.com/zh-HK/news/291115098.md) --- # Pre-market hot trades in US stocks: XCF Global up 14.94% in pre-market; INVO Fertility down 12.23% in pre-market **Pre-market Hot Trades in US Stocks** XCF Global, up 14.94% in pre-market trading, has no significant news recently. The trading is active with clear capital flows, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. INVO Fertility is down 12.23% in pre-market trading. Based on recent key news: 1. On June 25, INVO Fertility released its latest financial report, showing that the company's business model focuses on operating and expanding fertility clinics, with technical sentiment signals indicating a strong sell, leading to a decline in stock price. The average trading volume is 296,801, and the current market capitalization is $2.45 million. 2. On June 23, INVO Fertility announced that Nasdaq has officially closed its violation regarding delayed filing, confirming that the company is fully compliant with timely filing rules. Although this news brought some positive market sentiment, it failed to prevent the decline in stock price. 3. On June 22, INVO Fertility submitted its Form 10-Q, and Nasdaq staff confirmed that the company is fully compliant with timely filing rules, but concerns about future cash flow remain, leading to continued declines in stock price. The fertility and reproductive health industry has shown weakness recently, with significant capital outflows. **Top Gainers in Pre-market US Stocks** Nature's Way Pharmaceuticals is up 222.30% in pre-market trading. Based on recent key news: 1. On June 26, Nature's Way Pharmaceuticals announced the acquisition of Best Praise International Limited. This acquisition includes five Chinese patents from Best Praise, with a total purchase price of $10.751 million, paid through 4,376,552 shares of Nature's Way Pharmaceuticals' Class A common stock. This move aims to expand its pharmaceutical patent portfolio, significantly boosting the stock price. 2. On June 27, the market reacted positively to the acquisition news from Nature's Way Pharmaceuticals, with investors anticipating more R&D and commercialization opportunities for the company in the future, further driving up the stock price. 3. On June 27, analysts expressed approval of Nature's Way Pharmaceuticals' acquisition, believing that the company's focus on elderly healthcare will bring more development opportunities and enhance market confidence. The pharmaceutical industry has shown strong performance recently, with clear policy support. Decoy Therapeutics is up 207.90% in pre-market trading. Based on recent key news: 1. On June 26, Decoy Therapeutics announced a private financing of up to $21 million. This news has boosted market confidence in the company's future development, leading to a significant increase in stock price. 2. On June 26, Decoy Therapeutics launched its innovative product Designable Multi-Antivirals (D-MAVs™) in Houston. This product aims to target common viral mechanisms across multiple virus families, showcasing the company's leading position in antiviral therapies, further uplifting the stock price On June 26, the company's forward-looking statement indicated that despite risks in financing and product development, the company is confident about its future performance. These statements alleviated investor concerns and promoted a rise in stock prices. The biotechnology industry has performed strongly recently, with significant capital inflows. Inlif pre-market rose by 58.89%. Based on recent key news: 1. On June 26, TipRanks' AI analyst Spark rated Inlif stock as neutral, with a target price of $0.05. Spark pointed out that the financial performance in 2025 is expected to deteriorate sharply (loss results and negative cash flow), and the technical indicators are very weak (severely oversold momentum and prices far below major moving averages), leading to stock price volatility ### Related Stocks - [SAFX.US](https://longbridge.com/en/quote/SAFX.US.md) - [IVF.US](https://longbridge.com/en/quote/IVF.US.md) - [UPC.US](https://longbridge.com/en/quote/UPC.US.md) - [DCOY.US](https://longbridge.com/en/quote/DCOY.US.md) - [INLF.US](https://longbridge.com/en/quote/INLF.US.md) ## Related News & Research - [INVO Fertility signs equity purchase agreement for up to $15 million stock sales to Alumni Capital](https://longbridge.com/en/news/293798702.md) - [XCF Global Highlights Revenue-Generating Production and Commercial Progress](https://longbridge.com/en/news/294052057.md) - [XCF Global enters $400,000 senior secured loan with Hollywood Horizons at 25% OID](https://longbridge.com/en/news/293523813.md) - [Should you buy Procter & Gamble stock before July 29?](https://longbridge.com/en/news/293850370.md) - [Wealth Watch Advisors INC Purchases 2,385 Shares of Invesco QQQ $QQQ](https://longbridge.com/en/news/293917246.md)